Share Name Share Symbol Market Type Share ISIN Share Description
Ergomed LSE:ERGO London Ordinary Share GB00BN7ZCY67 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 177.00p 175.00p 180.00p 177.50p 176.00p 177.50p 4,155 16:35:21
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 47.6 -4.4 -11.0 - 79.40

Ergomed Share Discussion Threads

Showing 276 to 295 of 300 messages
Chat Pages: 12  11  10  9  8  7  6  5  4  3  2  1
DateSubjectAuthorDiscuss
01/7/2018
14:58
There is a recent report on Ergomed’s AGM which is available to read in our full member exclusive area here: hTTps://www.sharesoc.org/members-area/
sharesoc
29/6/2018
13:14
Ergomed to present to investors at the upcoming Proactive One2One Forum on 12th July in London. For details and registration, click here: https://tinyurl.com/ybq4tya2
aim_trader
28/6/2018
13:40
In a note to clients, analysts at Numis said that as Ergomed “is constantly hiring ahead of anticipated revenue growth”, a delay in anticipated revenue was going to drive margins lower as utilisation dropped. They added: “We downgrade our revenues by c.5% to £46.5mln primarily hitting the CRO division (£19.0mln from £21.6mln), with top line growth in PV [PrimeVigilance division] slightly higher, but on a higher cost base (reduced gross margins in both divisions) which effectively delays our EBITDA ramp by one year.” The broker was, however, fairly ambivalent regarding the delay: “Contract delays are a frequent occurrence in the CRO business, while in the PV division trading seems to have been in line with or slightly ahead of our expectations, while management planned for more.” hTTp://www.p roactiveinvestors.co.uk/companies/news/199777/ergomed-revenue-delay-leads-to-numis-downgrade-199777.html
sicilian_kan
28/6/2018
10:50
It is the companies second profits warning in the last year. Shares are now back to where they were a couple of months ago. I don't think you can complain you have been overly hard done by. The multiple is hardly cheap,
horndean eagle
28/6/2018
09:17
Yes, think disastrous RNS is probably a bit OTT - very disappointing more like it, especially given the Company's previous bullish statements.
bermudashorts
28/6/2018
09:12
what current market cap? Seems toppy..
tsmith2
28/6/2018
09:02
Mirabeau this isn't really a pharma stock. It is a CRO with a pharmacovigilance arm that it is expanding.
sicilian_kan
28/6/2018
08:46
What a mess. I only set up the thread and never held a position but how many pharma stocks in recent weeks have released seriously disastrous RNSs...too numerous to mention
mirabeau
28/6/2018
08:44
Seems completely overdone to me. - 5% reduction in revenue compared to market consensus, yet a 33% reduction in share price. - 2018 EBITDA still going to be ahead of 2017's £2.8m - Backlog of contracts still strong and increase on last years - The Company's cash position remains strong with positive cash flows in the period. I have only a small amount here. Invested 18 months ago on a 5 year basis. See no reason to bail out. Strategy and management still seem strong and am excited by the pharmacovigilance opportunities.
sicilian_kan
25/5/2018
16:44
Agreed and a nice rise too. I think we should be looking at testing 300p at some point in the coming weeks / months.
sicilian_kan
25/5/2018
07:45
Decent RNS this morning, Dr. Michael Forstner, ex Roche and Boehringer-Ingelheim appears to be a good appointment.
bermudashorts
25/5/2018
07:38
SP rise seems to confirm breakout above 212p area
18bt
24/5/2018
17:16
BlackRock, Inc. at 5%
mfhmfh
24/5/2018
14:19
positive write up in Shares magazine today.
mfhmfh
19/5/2018
14:20
Not the best analogy. Rome burned down!
jamtomorrow2
19/5/2018
11:12
Rome wasn't built in a day. But it was built.
sicilian_kan
18/5/2018
16:56
Presumably the co-partnership costs will continue at least in part for another year or so. And they’ve got to pay more for Haemostatix as well as any future acquisitions, which they certainly intend to make, so I’m not so convinced that profitability will be at the levels that you are predicting. I am also concerned about their accounting prowess bearing in mind the last minute profit warning when late adjustments of £900,000 were announced out of the blue.
ih_433513
18/5/2018
15:56
Strip out the R&D costs of the old co-partnering strategy (£2.7m) and the costs of acquisitions and they would have made a net profit. The core fundamentals of the business going forwards are very strong and the growth prospects are already proven to be very high.
sicilian_kan
18/5/2018
10:07
This is the link: https://www.youtube.com/watch?v=j5SSnJ9kDWc jamtomorrow, change in business strategy. Much higher growth in other less risky areas will be focused on - I see this as the prime driver behind the recent growth in sp: · Net service revenue growth of 36% driving total revenue growth of 21% · Within services, Drug Safety & Medical Information (pharmacovigilance) revenue grew 67% PrimeVigilance's strategy of investing in people and technology is designed to drive further growth with the aim of becoming the global leader in pharmacovigilance by 2020. The global pharmacovigilance market is forecast to grow to more than $8 billion by 2024 from around $3 billion in 2015, with contract outsourcing forecast to expand from around 30% of the market in 2015 to approximately 50% in 2024. [see results rns] "Net service revenue from the DS&MI segment, increased 68% to £22.3 million in 2017 from £13.3 million in 2016. Excluding the PharmInvent acquisition (completed in November 2016), organic growth of the DS&MI segment was 35%."
sicilian_kan
17/5/2018
12:08
They are now going to partner out the Phase 3 Haemostatix trial. I thought that was a rather odd decision. A CRO like Ergo could carry out the trial on the cheap but they elect to partner it out and presumably reduce their potential take by at least 50%. Anyway it’s taking a while to find a partner isn’t it? Also Ferrer seems to be struggling to find a partner to progress its insomnia drug. And finally I see that Cel-Sci is expecting the results from the Multikine Phase 3 shortly. That would be a nice surprise if the results were positive, which not many people are expecting.
jamtomorrow2
Chat Pages: 12  11  10  9  8  7  6  5  4  3  2  1
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20180721 03:32:22